A single-cell atlas refines colorectal cancer subtypes
Across ~487,829 cells from diverse CRC samples and cohorts, tumors show CMS-related programs plus immune/stromal continua; high CAF and C1Q+ TAM content track poorer outcomes and may simplify prognosis beyond bulk CMS alone.
Source
Refining colorectal cancer classification and clinical stratification through a single-cell atlas
Study at a glance
- Design
- Other — Single-cell atlas of CRC tumor/microenvironment relative to CMS, with external cohorts
- N
- N=16 · 16 primary patients (plus adjacent normals); ~487,829 cells across pooled cohorts
- Population
- Racially diverse CRC patients and external single-cell CRC cohorts
- Outcome
- Cellular CMS heterogeneity and CAF/C1Q+ TAM contributions to prognosis
Structured fields used in claim comparison tables when every cited study has a complete layer.
What they did
Authors argue bulk CMS mixes tumor and stroma, so they profiled racially diverse human CRC samples and multiple external cohorts (~487,829 single cells) to map cellular diversity in tumor and microenvironment compartments relative to consensus molecular subtypes (CMS).
What they found
Tumor cells recapitulate CMS subgroups but with significant intratumoral CMS heterogeneity. MSI-H (CMS1) and MSS tumors can look similar in epithelial pathway activation, yet MSI-H tumors show CD8+ cytotoxic T-cell infiltration patterns that help explain checkpoint-inhibitor responses. CRC transcriptomes form a tumor–immune–stromal continuum rather than only discrete bulk subtypes. Patients with high cancer-associated fibroblasts (CAFs) and C1Q+ TAM content have poorer outcomes; some CAF subtypes associate with immunotherapy resistance. Authors conclude CAF/C1Q+TAM signatures can explain much of CMS’s prognostic signal and may be therapeutically relevant.
The limits
What it doesn't show
Does not prove that depleting CAFs or C1Q+ TAMs improves immunotherapy in a randomized trial. Continuum language means bulk CMS labels are still useful but incomplete — not that subtypes are meaningless. Cohort composition and correction notes in the literature should be checked before treating every numeric detail as final.
Key terms
- CMS
- Consensus molecular subtypes of colorectal cancer from bulk transcriptomics.
- MSI-H / MSS
- Microsatellite instability–high vs microsatellite-stable tumor classes.
- CAF
- Cancer-associated fibroblast — stromal state linked to outcomes here.
- C1Q+ TAM
- C1Q-positive tumor-associated macrophage state associated with poorer outcomes in this atlas.
- Tumor–immune–stromal continuum
- Single-cell view that CRC profiles grade across compartments rather than only discrete bulk boxes.
Flashcards
Research intelligence for this paper
See its role on concept claims, tensions it is part of, placement history, and related discoveries.
Quiz yourself
Why isn’t bulk CMS enough for stroma questions?
Common questions
About how many cells entered the analyses?
About 487,829 single cells across cohorts.
Do tumor cells match CMS cleanly?
They recapitulate CMS subgroups but show significant intratumoral CMS heterogeneity.
What may help explain MSI-H checkpoint responses?
CD8+ cytotoxic T-cell phenotype infiltration in MSI-H CRCs.
Which stromal states tracked poorer outcomes?
High CAF and C1Q+ TAM content.
What simpler signature do authors propose?
One based on distinct CAFs and C1Q+ TAMs that could stratify prognosis with greater precision than CMS alone.
More on Gene expression